Back to Search
Start Over
Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes
- Source :
- British Journal of Cancer, British Journal of Cancer, Cancer Research UK, 2019, 120 (9), pp.913-921. ⟨10.1038/s41416-019-0420-y⟩, Bonnefoi, H, MacGrogan, G, Poncet, C, Iggo, R, Pommeret, F, Grellety, T, Larsimont, D, Becette, V, Kerdraon, O, Bibeau, F, Ghnassia, J-P, Picquenot, J-M, Thomas, J, Tille, J-C, Slaets, L, Bodmer, A, Bergh, J & Cameron, D 2019, ' Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes ', British Journal of Cancer . https://doi.org/10.1038/s41416-019-0420-y, British Journal of Cancer, 120 (9, British Journal of Cancer, Vol. 120, No 9 (2019) pp. 913-921
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Background: We explored, within the EORTC10994 study, the outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry (IHC) as androgen-receptor (AR) positive, oestrogen (ER) and progesterone (PR) negative. We also assessed the concordance between IHC and gene expression arrays (GEA) in the identification of MA cancers. Methods: Centrally assessed biopsies for AR, ER, PR, HER2 and Ki67 by IHC were classified into six subtypes: MA, triple-negative (TN) basal-like, luminal A, luminal B HER2 negative, luminal B HER2 positive and “other”. The two main objectives were the pCR rates and survival outcomes in the overall MA subtype (and further divided by HER2 status) and the remaining five subtypes. Results: IHC subtyping was obtained in 846 eligible patients. Ninety-three (11%) tumours were classified as the MA subtype. Both IHC and GEA data were available for 64 patients. In this subset, IHC concordance was 88.3% in identifying MA tumours compared with GEA. Within the MA subtype, pCR was observed in 33.3% of the patients (95% CI: 29.4–43.9) and the 5-year recurrence-free interval was 59.2% (95% CI: 48.2–68.6). Patients with MA and TN basal-like tumours have lower survival outcomes. Conclusions: Irrespective of their HER2 status, the prognosis for MA tumours remains poor and adjuvant trials evaluating anti-androgens should be considered.<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Receptor, ErbB-2
Concordance
medicine.medical_treatment
Breast Neoplasms
[SDV.CAN]Life Sciences [q-bio]/Cancer
ddc:616.07
Disease-Free Survival
Article
03 medical and health sciences
Breast cancer
0302 clinical medicine
[SDV.CAN] Life Sciences [q-bio]/Cancer
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Survival rate
Chemotherapy
business.industry
Gene Expression Profiling
Apocrine
medicine.disease
Immunohistochemistry
Subtyping
3. Good health
Cancérologie
ErbB Receptors
Survival Rate
Clinical trial
Biological sciences
Treatment Outcome
Receptors, Estrogen
Chemotherapy, Adjuvant
Receptors, Androgen
[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
030220 oncology & carcinogenesis
[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
Female
Receptors, Progesterone
business
Subjects
Details
- ISSN :
- 15321827 and 00070920
- Volume :
- 120
- Database :
- OpenAIRE
- Journal :
- British Journal of Cancer
- Accession number :
- edsair.doi.dedup.....8075ed5bffb4cfbba37e33a4360db84c